Abstract: 【Abstract】 Psoriasis is an immune-mediated chronic, systemic, inflammatory disease characterized by recurrent episodes. Long-term disease management is essential for disease control, delaying disease progression, and preventing the development of comorbidities. In recent years, biologic agents have gradually become an important systemic treatment option for the long-term management of moderate-to-severe plaque psoriasis and have demonstrated favorable efficacy. Based on recent advances in research on the long-term use of biologic agents for plaque psoriasis, as well as national and international guidelines and consensus statements on biologic therapy for psoriasis, and incorporating the clinical experience of experts, this consensus addresses 15 clinical questions in four major domains, including the efficacy and maintenance strategies of long-term biologic therapy （48 weeks to 10 years）, safety, management of special populations （e.g., older adults）, and comorbidity management. A total of 23 recommendations were developed to provide guidance for the standardized long-term use of biologic agents in plaque psoriasis, with the aim of optimizing treatment strategies and improving clinical outcomes.

Key words: Psoriasis, Biologic agents, Case management, Aged, Comorbidity, Plaque psoriasis, Expert consensus